Correlation of degree of acute radiation dermatitis (RD) with skin dose distribution in head and neck squamous cell carcinoma patients treated with definitive concurrent chemoradiation
Abstract
Background: Radiation dermatitis (RD) or skin toxicity is one of the most common acute side effects of radiation in head and neck cancer patients. This study aims to correlate the pattern of volumetric-modulated arc therapy (VMAT) dose distribution to the skin with the grades of RD.
Materials and methods: 80 plans of histopathologically proven squamous cell carcinoma head and neck patients already treated with definitive concurrent chemoradiation [66–70 Gy in 33–35# or 66 Gy in 30# in simultaneous integrated boost (SIB), with concurrent Cisplatin 100 mg/m2 3 weekly] at our institution between November 2022 and November 2023 were retrieved from our digital archives.
For each plan, 1 ring structure was created 3mm below the external skin surface, and the parameters V40, V50, V60 and Dmax were collected from the same. These parameters were correlated with grades of RD as per per Common Terminology Criteria for Adverse Events (CTCAE) v5.0.
The statistical analysis was done using MedCalc software version 22.021.
Results: The incidence of G2/G3 RD was 52.5%, and its incidence was significantly correlated with all of the four parameters. Statistically significant (p < 0.001) dosimetric predictive accuracy was provided by 71.66 cc, 29.98 cc and 7.624 cc of the 3mm skin ring V40, V50 and V60, respectively.
Conclusion: The dose distribution pattern to a skin layer stationed 3mm below the surface may help predict the development of severe RD in head and neck cancer patients receiving concurrent chemoradiation.
Keywords: head and neck cancerpredictive accuracyradiation dermatitissquamous cell carcinoma
References
- Hymes SR, Strom EA, Fife C. Radiation dermatitis: clinical presentation, pathophysiology, and treatment 2006. J Am Acad Dermatol. 2006; 54(1): 28–46.
- Bentzen SM, Trotti A. Evaluation of early and late toxicities in chemoradiation trials. J Clin Oncol. 2007; 25(26): 4096–4103.
- Nutting CM, Morden JP, Harrington KJ, et al. PARSPORT trial management group. Parotid-sparing intensity modulated versus conventional radiotherapy in head and neck cancer (PARSPORT): a phase 3 multicentre randomised controlled trial. Lancet Oncol. 2011; 12(2): 127–136.
- Shinde P, Jadhav A, Shankar V, et al. Assessment of dosimetric impact of interfractional 6D setup error in tongue cancer treated with IMRT and VMAT using daily kV-CBCT. Rep Pract Oncol Radiother. 2023; 28(2): 224–240.
- Koiwai K, Hirasawa D, Sugimura M, et al. Impact of upgraded radiotherapy system on outcomes in postoperative head and neck squamous cell carcinoma patients. Rep Pract Oncol Radiother. 2022; 27(6): 954–962.
- Lee N, Chuang C, Quivey JM, et al. Skin toxicity due to intensity-modulated radiotherapy for head-and-neck carcinoma. Int J Radiat Oncol Biol Phys. 2002; 53(3): 630–637.
- Brodin NP, Tomé WA. Revisiting the dose constraints for head and neck OARs in the current era of IMRT. Oral Oncol. 2018; 86: 8–18.
- NCCN guidelines. Head and Neck Cancers, version 2.2023. http://www.nccn.org.
- Serón-Arbeloa C, Labarta-Monzón L, Puzo-Foncillas J, et al. Malnutrition Screening and Assessment. Nutrients. 2022; 14(12): 2392.
- Grégoire V, Evans M, Le QT, et al. Delineation of the primary tumour Clinical Target Volumes (CTV-P) in laryngeal, hypopharyngeal, oropharyngeal and oral cavity squamous cell carcinoma: AIRO, CACA, DAHANCA, EORTC, GEORCC, GORTEC, HKNPCSG, HNCIG, IAG-KHT, LPRHHT, NCIC CTG, NCRI, NRG Oncology, PHNS, SBRT, SOMERA, SRO, SSHNO, TROG consensus guidelines. Radiother Oncol. 2018; 126(1): 3–24.
- Studer G, Brown M, Salgueiro EB, et al. Grade 3/4 dermatitis in head and neck cancer patients treated with concurrent cetuximab and IMRT. Int J Radiat Oncol Biol Phys. 2011; 81(1): 110–117.
- Bonomo P, Talamonti C, Desideri I, et al. Analysis of skin dose distribution for the prediction of severe radiation dermatitis in head and neck squamous cell carcinoma patients treated with concurrent chemo-radiotherapy. Head Neck. 2020; 42(2): 244–253.
- Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 . https://ctep.cancer.gov/protocoldevelopment/electronic_applications/docs/ctcae_v5_quick_reference_5x7.pdf.
- Nahm FS. Nonparametric statistical tests for the continuous data: the basic concept and the practical use. Korean J Anesthesiol. 2016; 69(1): 8–14.
- Kim HY. Statistical notes for clinical researchers: Chi-squared test and Fisher's exact test. Restor Dent Endod. 2017; 42(2): 152–155.
- Fluss R, Faraggi D, Reiser B. Estimation of the Youden Index and its associated cutoff point. Biom J. 2005; 47(4): 458–472.
- Gutiontov SI, Shin EJ, Lok B, et al. Intensity-modulated radiotherapy for head and neck surgeons. Head Neck. 2016; 38 Suppl 1(Suppl 1): E2368–E2373.
- Grégoire V, Langendijk JA, Nuyts S. Advances in Radiotherapy for Head and Neck Cancer. J Clin Oncol. 2015; 33(29): 3277–3284.
- Price RA, Koren S, Veltchev I, et al. Planning target volume-to-skin proximity for head-and-neck intensity modulated radiation therapy treatment planning. Pract Radiat Oncol. 2014; 4(1): e21–e29.
- Penoncello GP, Ding GX. Skin dose differences between intensity-modulated radiation therapy and volumetric-modulated arc therapy and between boost and integrated treatment regimens for treating head and neck and other cancer sites in patients. Med Dosim. 2016; 41(1): 80–86.
- Teoh M, Clark CH, Wood K, et al. Volumetric modulated arc therapy: a review of current literature and clinical use in practice. Br J Radiol. 2011; 84(1007): 967–996.
- Mir R, Kelly S, Xiao Y, et al. Organ at risk delineation for radiation therapy clinical trials: Global Harmonization Group consensus guidelines. Radiother Oncol . 2020; 150: 30–39.
- Mori M, Cattaneo GM, Dell'Oca I, et al. Skin DVHs predict cutaneous toxicity in Head and Neck Cancer patients treated with Tomotherapy. Phys Med. 2019; 59: 133–141.